Moderna Says its Vaccine is Highly Effective in Preventing COVID-19

Headline Roundup November 16th, 2020

The biotech company Moderna said Monday that its experimental vaccine is 94.5% effective in preventing the COVID-19 coronavirus, according to analysis of its clinical trial.

Final results are expected in as soon as a few weeks, and vaccines from both Moderna and Pfizer could be available on a limited basis by the end of the year.

Moderna Says its Vaccine is Highly Effective in Preventing COVID-19

From the Right
13320
coronavirus, coronavirus vaccines, Moderna, Pfizer

Moderna’s coronavirus vaccine was nearly 95% effective and thwarted severe disease in an interim analysis, the company said Monday, putting a second drugmaker on track to request emergency approval before the end of the year.

The Cambridge, Massachusetts, company said it counted 95 cases within its trial of 30,000 participants. Only five of them were in the vaccine arm of the trial, versus 90 in the placebo group.

It also looked at 11 severe cases of COVID-19 and found that all of those participants received the dummy shots, not the...

Read full story
From the Center
13320

A second COVID-19 candidate vaccine looks to be even more effective than the first, with both protecting more than 90% of those who get the shots.

Moderna, a Cambridge, Massachusetts-based biotechnology company, announced early Monday that its candidate vaccine, mRNA-1273, developed in collaboration with the U.S. government, appears to be 94.5% effective against the disease.

Earlier this month, Pfizer and its German partner BioNTech, announced early effectiveness data, showing their vaccine, called BNT162b2, had protected more than 90% of those who received it.

Both results are preliminary, with final...

Read full story
From the Left
13320

Biotechnology firm Moderna announced Monday that a preliminary analysis shows its experimental coronavirus vaccine is nearly 95 percent effective at preventing illness, including severe cases — a striking initial result that leaves the United States with the prospect that two coronavirus vaccines could be available on a limited basis by the end of the year.

The news comes a week after pharmaceutical giant Pfizer and its German partner BioNTech lifted the stock market and people’s hopes with the news that their coronavirus vaccine was more than 90 percent effective.

Based...

Read full story

Try the New AllSides Mobile App

The only news app you’ll ever need. Now available on iOS and Android.